Merck eyes new bladder cancer space with positive Keytruda trial in muscle-invasive disease

Merck’s Keytruda is riding a winning streak in bladder cancer.

Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in localized muscle-invasive and locally advanced urothelial carcinoma.